Abstract: Systems and methods for improving the delivery of interactive advertisements are discussed herein. Systems and methods include approaches and solutions for boosting the rank of certain ads and/or ad types based on a combination of their interaction type and an ad interaction history for a given user, vertical, or aggregate indicator. Systems and methods also include suppressing ads unlikely to be interacted with from ranking and format boosting based on such ad interaction history.

Abstract: Systems and methods for pre-loading and displaying intervening content, such as advertisements, on a mobile device during latency periods, such as when an advertiser landing page is requested by that device, are provided herein. Intervening content may be pre-loaded on to the device and associated with one or more particular advertisements such that selecting/interacting with the associated advertisement triggers intervening content display during known or detected periods of latency. In some cases, a latency threshold or thresholds may determine one or more types of content to present, and/or a content presentation sequence.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of fibroblast growth factor receptor 4 (FGFR4). The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding fibroblast growth factor receptor 4. Methods of using these compounds for modulation of fibroblast growth factor receptor 4 expression and for treatment of diseases associated with expression of fibroblast growth factor receptor 4 are provided.

Abstract: Systems and methods for estimating the minimum geographic coverage of a wireless base station. In an embodiment, the present invention estimates coverage by (1) receiving real-time wireless base station information from the mobile device; (2) extracting a set of location points and system specific information based on the real-time wireless base station information; (3) determining a coverage area based on the set of location points and the system specific information; (4) adjusting for errors based on various factors (5) storing the determined coverage area.

Abstract: Compounds, compositions and methods are provided for modulating the levels expression, processing and function of pri-miRNAs. In particular, methods and compounds are provided for the modulation of the levels, expression, processing or function of polycistronic pri-miRNAs. The compositions comprise oligomeric compounds targeted to small non-coding RNAs and pri-miRNAs. Further provided are methods for selectively modulating pri-miRNA levels in a cell. Also provided are methods for identifying oligomeric compounds that result in increase pri-miRNA levels when contacted with a cell.

Abstract: A cardio electrotherapy lead is disclosed herein. In one embodiment, the lead includes a tubular body, a conductor cable and an electrode. The conductor cable longitudinally extends through the tubular body and includes a distal end. The electrode is located on the tubular body and includes an attachment mechanism mechanically coupling the lead distal end to the electrode.

Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.

Abstract: This specification describes technologies relating to geographically localizing mobile communication devices. In general, one aspect of the subject matter described in this specification can be embodied in a method that includes receiving information corresponding to a location of a wireless landmark in a mobile communication network. The method also includes communicating with the wireless landmark to estimate the location of a first node in the mobile communication network proximate to the wireless landmark. Other embodiments of this aspect include corresponding systems, apparatus, and computer program products.

Abstract: This invention provides a process for the detoxification of chemical agents including chemical warfare agents such as sulfur mustards, nitrogen mustards, nerve agents of G and V type, lewisite and adamsite by reacting the chemical agents with hydroxyl radicals at a pH greater than 7.0 to detoxify the agents and to render them suitable for disposal. The process can be used on-site and can be easily scaled to fairly large sizes.

Abstract: Systems and methods for estimating the minimum geographic coverage of a wireless base station. In an embodiment, the present invention estimates coverage by (1) receiving real-time wireless base station information from the mobile device; (2) extracting a set of location points and system specific information based on the real-time wireless base station information; (3) determining a coverage area based on the set of location points and the system specific information; (4) adjusting for errors based on various factors (5) storing the determined coverage area.

Abstract: A wireless base station allows a mobile device to communicate with a wireless network. An estimate of the location of the wireless base station may allow a location based service to determine the location of a mobile device. In an embodiment, location may be estimated using a collection of data samples obtained from a mobile device. These data samples may contain carrier related timing information, for example GSM (Global System for Mobile Communications) timing information and received signal strength indication (RSSI). Data from the GSM timing information and RSSI may be analyzed to estimate a distance of a mobile device from a wireless base station. In another embodiment, a centroid of the data samples is computed. The centroid may then be used to estimate the direction of a cell phone tower relative to the centroid. In this way, using an estimate of distance and direction, location of wireless base station may be estimated.

Abstract: A method and system for accuracy analysis of wireless base station location is provided. In one embodiment, data from a set of mobile devices using a wireless base station is collected. A location of a wireless base station is estimated based on locations of the mobile devices (i.e. points) in the collected set. To provide a more accurate location estimation for the wireless base station, the estimated location is analyzed for accuracy based on the collected data. A confidence score is calculated using a weight function with weights for the collected data based on factors, such as, collection size, platform types of the mobile devices, quality, temporal diversity and/or spatial diversity of points corresponding to the mobile devices, etc. An estimated location of the wireless base station may be adjusted based on the calculated confidence score. An estimated coverage region of the wireless base station may be also estimated and adjusted.

Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.

Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of PTPRU in a cell, tissue or animal. Also provided are methods of active target segment validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and/or treatment of diabetes, obesity, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hyperfattyacidemia, liver steatosis, steatohepatitis, non-alcoholic steatohepatitis, metabolic syndrome, cardiovascular disease and coronary heart disease by administration of antisense compounds targeted to PTPRU.

Abstract: Compounds, compositions and methods are provided for modulating the expression of eIF4E-BP2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding eIF4E-BP2. Methods of using these compounds for modulation of eIF4E-BP2 expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E-BP2 are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.

Abstract: An implantable cardioverter defibrillator (ICD) including a set of leads having electrodes disposed therein. The electrodes may include a weld electrode connected to an internal wire of the lead and the ICD and a tip electrode. The tip electrode may have a set of grooves or cut out regions in its outer surface to provide edge effects for currents applied through the tip electrode. The grooves or cut out regions may form gaps in the surface of the tip electrode exposing a medical compound that is housed within the tip electrode. The medical compound may elute through the gaps.

Abstract: In general, one aspect of the subject matter described in this specification can be embodied in methods that include the actions of identifying a target region and an exclusion region of the target region, where the target region encompasses the exclusion region. A target user is identified within the target region and not within the exclusion region encompassed by the target region. A target advertisement is selected for the target user based on the target user being within the target region and not within the exclusion region encompassed by the target region. The target advertisement is sent to the target user. An exclusion user is identified within the exclusion region encompassed by the target region. An exclusion advertisement different from the target advertisement is selected for the exclusion user based on the exclusion user being with the exclusion region. The exclusion advertisement is sent to the exclusion user.